Cakir, E.Saydan, D.Gulbagci, B.Ozen, M.Ugurlu, IDemirci, A.Bilir, F.2024-05-192024-05-1920231128-3602https://hdl.handle.net/20.500.12713/4972- OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immuni-ty in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sino-vac-CoronaVac COVID-19 vaccine immunogenici-ty and compared it with natural COVID-19 disease in cancer patients during their cancer therapy.PATIENTS AND METHODS: A total of 111 pa-tients with cancer and who are on active treat-ment were included in the study. This is a sin-gle-center study and was designed prospec-tively. Two group of patients were included in the study, natural disease and vaccinated group.RESULTS: A total of 111 patients were in-cluded in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while af-ter the second dose of vaccine were 2.6 (1.0-7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immu-notehrapy/targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference be-tween the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively].CONCLUSIONS: The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving ac-tive systemic therapy. On the other hand, nat-ural disease immunogenicity was higher than vaccinated group.eninfo:eu-repo/semantics/closedAccessCovid-19CancerChemotherapyImmunogenecityArticle2794309431537203857WOS:0009998969000292-s2.0-85159769767N/AQ2